SG11201408101TA - Vaccination with interleukin-4 antagonists - Google Patents

Vaccination with interleukin-4 antagonists

Info

Publication number
SG11201408101TA
SG11201408101TA SG11201408101TA SG11201408101TA SG11201408101TA SG 11201408101T A SG11201408101T A SG 11201408101TA SG 11201408101T A SG11201408101T A SG 11201408101TA SG 11201408101T A SG11201408101T A SG 11201408101TA SG 11201408101T A SG11201408101T A SG 11201408101TA
Authority
SG
Singapore
Prior art keywords
methods
international
antigen
interleukin
australian
Prior art date
Application number
SG11201408101TA
Other languages
English (en)
Inventor
Ronald James Jackson
Charani Ranasinghe
Original Assignee
Univ Australian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012902345A external-priority patent/AU2012902345A0/en
Application filed by Univ Australian filed Critical Univ Australian
Publication of SG11201408101TA publication Critical patent/SG11201408101TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
SG11201408101TA 2012-06-05 2013-06-05 Vaccination with interleukin-4 antagonists SG11201408101TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2012902345A AU2012902345A0 (en) 2012-06-05 Vaccination with Interleukin-4 Antagonists
PCT/AU2013/000589 WO2013181696A1 (en) 2012-06-05 2013-06-05 Vaccination with interleukin-4 antagonists

Publications (1)

Publication Number Publication Date
SG11201408101TA true SG11201408101TA (en) 2015-01-29

Family

ID=49711200

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201408101TA SG11201408101TA (en) 2012-06-05 2013-06-05 Vaccination with interleukin-4 antagonists

Country Status (15)

Country Link
US (1) US20150150963A1 (ja)
EP (2) EP2854837A4 (ja)
JP (1) JP2015520175A (ja)
KR (1) KR20150021088A (ja)
CN (1) CN104717971A (ja)
AU (1) AU2013271338B2 (ja)
BR (1) BR112014030436A2 (ja)
CA (1) CA2875683A1 (ja)
HK (1) HK1203358A1 (ja)
IL (1) IL236092A0 (ja)
IN (1) IN2014DN10408A (ja)
NZ (1) NZ702721A (ja)
SG (1) SG11201408101TA (ja)
WO (1) WO2013181696A1 (ja)
ZA (1) ZA201409076B (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019505554A (ja) * 2016-02-19 2019-02-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｉｌ−４ｒアンタゴニストを投与することによるワクチンの有効性を増強する方法
CN113527485A (zh) * 2020-04-17 2021-10-22 上海麦济生物技术有限公司 抗人白细胞介素-4受体α抗体及其制备方法和应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US7045313B1 (en) 1982-11-30 2006-05-16 The United States Of America As Represented By The Department Of Health And Human Services Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
JP3282188B2 (ja) 1991-06-27 2002-05-13 日本電気株式会社 半導体メモリ装置
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
DE69435169D1 (de) 1993-03-31 2009-01-02 Zeon Corp Polypeptid, dafür kodierende DNA, diese DNA beinhaltender, rekombinanter Vektor, Herstellung eines rekombinanten Virus unter Verwendung dieses Vektors und dessen Anwendung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
CN1112943C (zh) 1994-01-21 2003-07-02 粉剂注射疫苗股份有限公司 气体驱动的基因送递装置
GB9502879D0 (en) 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
US6265387B1 (en) 1995-10-11 2001-07-24 Mirus, Inc. Process of delivering naked DNA into a hepatocyte via bile duct
US6465634B1 (en) 1996-04-05 2002-10-15 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
AU3447097A (en) 1996-07-01 1998-01-21 Rhone-Poulenc Rorer S.A. Method for producing recombinant adenovirus
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
CA2316414A1 (en) 1997-12-23 1999-07-01 Introgene B.V. Adeno-associated virus and adenovirus chimeric recombinant viruses useful for the integration of foreign genetic information into the chromosomal dna of target cells
US7922709B2 (en) 1998-07-13 2011-04-12 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
US6972013B1 (en) 1998-07-13 2005-12-06 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
US7608273B2 (en) 1998-08-12 2009-10-27 University Of Western Ontario Recombinant lentivirus encoding modified GP 120 signal sequences
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
JP4693244B2 (ja) 1999-03-18 2011-06-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスのヘルパー無しの生産のための組成物および方法
AU778698B2 (en) 1999-04-29 2004-12-16 Miltenyi Biotec B.V. & Co. KG Method and means for producing high titer, safe, recombinant lentivirus vectors
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US7125705B2 (en) 2000-04-28 2006-10-24 Genzyme Corporation Polynucleotides for use in recombinant adeno-associated virus virion production
SI1407033T1 (sl) 2002-05-16 2006-06-30 Bavarian Nordic As Intergenske regije kot insercijska mesta v genomumodificiranega virusavakcinije Ankara (MVA)
AU2003263653A1 (en) 2002-09-27 2004-04-19 Daewoong Co., Ltd. A vaccine enhancing the protective immunity to hepatitis c virus using plasmid dna and recombinant adenovirus
US8287879B2 (en) * 2003-10-16 2012-10-16 The Regents Of The University Of California Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use
US20080131940A1 (en) 2004-06-25 2008-06-05 Robert Chiu Target Cell-Specific Short Interfering Rna and Methods of Use Thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
US8048404B1 (en) 2005-01-04 2011-11-01 Gp Medical, Inc. Pharmaceutical composition of nanoparticles for protein drug delivery
US7541046B1 (en) 2005-01-04 2009-06-02 Gp Medical, Inc. Nanoparticles for protein drug delivery
US7611690B2 (en) 2005-01-04 2009-11-03 Gp Medical, Inc. Nanoparticles for protein drug delivery
CA2605924A1 (en) 2005-04-24 2006-11-02 Acambis Inc. Recombinant flavivirus vaccines
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
MX2008008968A (es) * 2006-01-11 2008-09-10 Aerovance Inc Metodos y composiciones para tratar asma en primates humanos y no humanos.
US20090068195A1 (en) * 2007-04-23 2009-03-12 Wyeth Methods and compositions for treating and monitoring treatment of il-13-associated disorders
US20120088814A1 (en) * 2009-03-31 2012-04-12 Isis Pharmaceuticals, Inc. Methods of modulating an immune response to a viral infection
WO2011003138A1 (en) * 2009-07-06 2011-01-13 The Australian National University Immunomodulating compositions comprising interleukin 13 inhibitors and uses therefor

Also Published As

Publication number Publication date
KR20150021088A (ko) 2015-02-27
AU2013271338B2 (en) 2018-05-24
ZA201409076B (en) 2017-06-28
CA2875683A1 (en) 2013-12-12
CN104717971A (zh) 2015-06-17
EP3530283A1 (en) 2019-08-28
IN2014DN10408A (ja) 2015-08-14
NZ702721A (en) 2016-11-25
BR112014030436A2 (pt) 2017-09-26
EP2854837A1 (en) 2015-04-08
US20150150963A1 (en) 2015-06-04
IL236092A0 (en) 2015-01-29
WO2013181696A1 (en) 2013-12-12
JP2015520175A (ja) 2015-07-16
AU2013271338A1 (en) 2015-01-15
HK1203358A1 (en) 2015-10-30
EP2854837A4 (en) 2016-06-29

Similar Documents

Publication Publication Date Title
SG11201407200TA (en) Liquid formulation
SG11201804411TA (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201808990QA (en) Compositions for topical application of compounds
SG11201811432WA (en) Rna for cancer therapy
SG11201811363YA (en) Anti-zika virus antibodies and methods of use
SG11201407919WA (en) Carboxamide or sulfonamide substituted thiazoles and related derivatives as modulators for the orphan nuclear receptor ror[gamma]
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201407486PA (en) Compositions and methods for modulating utrn expression
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201809764XA (en) Humanized anti-il-1r3 antibodies
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201407995RA (en) Stabilized gp120
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201901438VA (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
SG11201407988UA (en) Process for improved opioid synthesis
SG11201809594WA (en) Nicotine particles and compositions
SG11201907420VA (en) Inhibition of smarca2 for treatment of cancer
SG11201810143PA (en) Exon skipping oligomers for muscular dystrophy
SG11201909495PA (en) Combination cancer immunotherapy with pentaaza macrocyclic ring complex
SG11201810786RA (en) [bis(trihydrocarbylsilyl)aminosilyl]-functionalized styrene and a method for its preparation
SG11201909735YA (en) Therapeutic compounds and compositions, and methods of use thereof
SG11201408262XA (en) Temperature stable vaccine formulations